Pharmaceuticals
10 health economics and outcomes research experts
These ten professionals have led health economics and outcomes research work at pharmaceutical and biotech companies, with titles such as Director, Health Economics and Outcomes Research. A reader can learn how drug companies plan and build evidence on the value of their products.
Professionals to explore
01—10Adeline Durand
LinkedInExperience: Director, Health Economics & Outcomes Research · Vertex Pharmaceuticals
Director, Health Economics & Outcomes Research at Vertex Pharmaceuticals since February 2026 and Associate Director, Health Economics & Outcomes Research there from 2022 to 2026. Other listed roles include HEOR Manager at Novartis (2019–2022), HEOR Manager at Merck Group (2018–2019) and Health Economics Advisor at Eli Lilly and Company (2016–2017).
Agathe Le Lay
LinkedInExperience: Director and Head of Health Economics & Outcomes Research · Lundbeck
Director and Head of Health Economics & Outcomes Research at Lundbeck since November 2017, alongside the role of Vice President, Head of Global Value Evidence & Patient Insights at H. Lundbeck A/S since February 2023. Other listed roles include Senior Director Value Evidence at Lundbeck (2019–2023) and Market Access Manager at Lundbeck (2008–2010).
Ankur A. Dashputre
LinkedInExperience: Director, Health Economics and Outcomes Research · BioNTech SE
Director, Health Economics and Outcomes Research at BioNTech SE since January 2024. Former Director, HEOR (2023–2024) and Associate Director, HEOR (2021–2023) at Bausch Health Companies Inc. The profile cites experience and peer-reviewed publications in real world evidence using large database analytics, health economic modeling and systematic literature reviews.
Bhavik J. Pandya
LinkedInExperience: Global Director, Health Economics and Outcomes Research (HEOR) Oncology · Astellas Pharma
Former Global Director, Health Economics and Outcomes Research (HEOR) Oncology (2022–2024) and Director, US Oncology Health Economics and Outcomes Research (2016–2022) at Astellas Pharma. Lead, Global Value Evidence Oncology, Prostate Cancer Portfolio at Astellas Pharma since August 2024, where the profile describes developing and executing global value evidence strategies for XTANDI and pipeline assets in prostate cancer.
Bhavini P. Srivastava
LinkedInExperience: Director, Health Economics and Outcomes Research · AbbVie
Director, Health Economics and Outcomes Research at AbbVie since April 2022; the profile headline names the role as HEOR Strategy Lead for Imbruvica and Etentamig. Former Associate Director, Global Value and HEOR at Jazz Pharmaceuticals (2019–2022) and Manager, Health Economics and Outcomes Research at Pharmacyclics, an AbbVie Company (2015–2018).
Brooke S. Harrow
LinkedInExperience: Senior Director, Health Economics and Outcomes Research · Deciphera Pharmaceuticals
Senior Director, Health Economics and Outcomes Research at Deciphera Pharmaceuticals since April 2021. Former Director, Global HEOR at Ipsen (2019–2021), Director, Health Economics and Outcomes Research at TESARO, Inc. (2015–2019) and Senior Director and Head, Health Economics and Outcomes Research at Meda in the US (2013–2015).
Gabrielle Williams
LinkedInExperience: Executive Director, Field HEOR · Bristol Myers Squibb
Executive Director, Field HEOR at Bristol Myers Squibb since June 2026. Former Senior Director, Field Health Economics & Outcomes Research (2025–2026) and Director, Field HEOR & Scientific Excellence (2023–2025) at Bristol Myers Squibb. The profile describes a focus on advancing healthcare solutions and improving patient access to the BMS portfolio.
Joelle Hallak
LinkedInExperience: Director, Global Health Economics and Outcomes Research, Strategy Lead · AbbVie
Director, Global Health Economics and Outcomes Research, Strategy Lead at AbbVie since November 2023, and Associate Director, Health Economics and Outcomes Research, Real-World Evidence at AbbVie from 2021 to 2023. The profile cites strategic experience in evidence generation and value demonstration across the asset lifecycle. Former Executive Director, Ophthalmic Clinical Trials and Translational Center at UIC Department of Ophthalmology and Visual Sciences (2015–2020).
Kyle Hvidsten
LinkedInExperience: Executive Director, HEOR · Alnylam Pharmaceuticals
Executive Director, HEOR at Alnylam Pharmaceuticals since January 2026. Former Head of Specialty Care Global HEVA and RWE (2020–2025) and Head of Global Health Economics and Value Assessment (HEVA) (2017–2020) at Sanofi, and Head of Global Health Economics at Vertex Pharmaceuticals (2011–2013). The profile cites experience leading teams in pricing strategy, reimbursement negotiations and evidence generation.
Xingdi Hu
LinkedInExperience: Director, Health Economics & Outcome Research (HEOR) Cardiovascular · Novartis
Director, Health Economics & Outcome Research (HEOR) Cardiovascular at Novartis since August 2021. Former Associate Director, Global Value & Access at Kiniksa Pharmaceuticals (2020–2021) and Senior Manager, Global Health Economics and Outcome Research at Vertex Pharmaceuticals (2018–2020). The profile summary cites experience leading global HEOR and market access strategies for new product launches and HTA submissions.
Choose the right perspective
Match the person's focus to your question, since global value strategy, US payer evidence and field-based health economics teams solve different problems. Also ask which therapeutic areas and markets the person has supported, because payer expectations and assessment rules differ by country and disease.
Questions to take into the conversation
- 01When in development should a company start building its health economic model and value evidence plan?
- 02How do you choose between real-world data sources when payers question a trial-based value claim?
- 03What made a health technology assessment submission succeed or fail in your experience?
Reaching health economics and outcomes research experts
How can I contact one of these health economics and outcomes research experts?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 9 companies, including Vertex Pharmaceuticals, Lundbeck and BioNTech SE, based on profile data retrieved on October 3, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach health economics and outcomes research experts?
You choose the offer, starting at $5 per person. It includes Instant Expert's 20% fee, so an offer that pays the person $100 costs you $125. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot and may describe past or present roles. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.
Request a correction or removal